AU2009324037B2 - Methods for selecting protease resistant polypeptides - Google Patents

Methods for selecting protease resistant polypeptides Download PDF

Info

Publication number
AU2009324037B2
AU2009324037B2 AU2009324037A AU2009324037A AU2009324037B2 AU 2009324037 B2 AU2009324037 B2 AU 2009324037B2 AU 2009324037 A AU2009324037 A AU 2009324037A AU 2009324037 A AU2009324037 A AU 2009324037A AU 2009324037 B2 AU2009324037 B2 AU 2009324037B2
Authority
AU
Australia
Prior art keywords
protease
polypeptide
seq
polypeptides
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009324037A
Other languages
English (en)
Other versions
AU2009324037A1 (en
Inventor
Carolyn Enever
Laurent Jespers
Malgorzata Pupecka
Ian M. Tomlinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2009324037A1 publication Critical patent/AU2009324037A1/en
Application granted granted Critical
Publication of AU2009324037B2 publication Critical patent/AU2009324037B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
AU2009324037A 2008-12-05 2009-12-04 Methods for selecting protease resistant polypeptides Ceased AU2009324037B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12013508P 2008-12-05 2008-12-05
US61/120,135 2008-12-05
PCT/EP2009/066395 WO2010063818A2 (en) 2008-12-05 2009-12-04 Methods for selecting protease resistant polypeptides

Publications (2)

Publication Number Publication Date
AU2009324037A1 AU2009324037A1 (en) 2010-06-10
AU2009324037B2 true AU2009324037B2 (en) 2015-07-30

Family

ID=42169477

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009324037A Ceased AU2009324037B2 (en) 2008-12-05 2009-12-04 Methods for selecting protease resistant polypeptides

Country Status (15)

Country Link
US (3) US8685895B2 (enExample)
EP (1) EP2364326B1 (enExample)
JP (2) JP5840498B2 (enExample)
KR (1) KR101740066B1 (enExample)
CN (1) CN102307897B (enExample)
AU (1) AU2009324037B2 (enExample)
BR (1) BRPI0922772B1 (enExample)
CA (1) CA2745448C (enExample)
EA (1) EA026508B1 (enExample)
ES (1) ES2688621T3 (enExample)
IL (1) IL212923A0 (enExample)
MX (1) MX2011005874A (enExample)
SG (1) SG194383A1 (enExample)
WO (1) WO2010063818A2 (enExample)
ZA (1) ZA201103575B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685895B2 (en) * 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
KR20130055663A (ko) * 2010-08-20 2013-05-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 개선된 항-혈청 알부민 결합 변이체
EP2866029B1 (en) * 2012-06-22 2017-05-03 Olympus Corporation Method for preparing sample containing pancreatic juice component, and kit for storing biological sample containing pancreatic juice component at room temperature
AU2014290229A1 (en) * 2013-07-15 2016-02-18 North Carolina State University Protease-resistant peptide ligands
JP6422977B2 (ja) * 2013-08-30 2018-11-14 エイプリルバイオ カンパニー リミテッド 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法
WO2016191659A1 (en) * 2015-05-28 2016-12-01 Bio-Rad Laboratories, Inc. Affinity ligands and methods relating thereto
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
JP6766253B2 (ja) * 2017-03-28 2020-10-07 森永乳業株式会社 新規ビフィドバクテリウム属細菌
KR20210143766A (ko) * 2019-02-26 2021-11-29 트위스트 바이오사이언스 코포레이션 Glp1 수용체에 대한 변이체 핵산 라이브러리
US11584781B2 (en) * 2019-12-30 2023-02-21 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US12391762B2 (en) 2020-08-26 2025-08-19 Twist Bioscience Corporation Methods and compositions relating to GLP1R variants
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
WO2008149143A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009121804A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
DK1801214T3 (da) 1997-07-07 2011-01-24 Medical Res Council In vitro sorteringsfremgangsmåde
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ATE380865T1 (de) 1998-05-13 2007-12-15 Domantis Ltd Phagen-display-selektionssystem für korrekt gefaltete proteine
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2003523742A (ja) 2000-02-03 2003-08-12 ドマンティス リミテッド コンビナトリアルタンパク質ドメイン
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
PT1737962E (pt) 2004-03-24 2010-12-03 Domantis Ltd Sequência líder universal gas1
CA2589800A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
MX2009003400A (es) * 2006-10-03 2009-04-28 Cadila Healthcare Ltd Compuestos antidiabeticos.
US8685895B2 (en) * 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
EA027866B1 (ru) * 2009-02-19 2017-09-29 Глэксо Груп Лимитед Улучшенные связывающие сывороточный альбумин варианты

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
WO2008149143A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009121804A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARMSEN, M.M. Applied Microbiology Biotechnology. 2006, vol. 72, pages 544-551 *

Also Published As

Publication number Publication date
CA2745448A1 (en) 2010-06-10
CN102307897B (zh) 2016-01-20
JP2012510803A (ja) 2012-05-17
ZA201103575B (en) 2012-01-25
US20110229458A1 (en) 2011-09-22
EP2364326A2 (en) 2011-09-14
SG194383A1 (en) 2013-11-29
US20140187750A1 (en) 2014-07-03
IL212923A0 (en) 2011-07-31
KR101740066B1 (ko) 2017-05-25
EP2364326B1 (en) 2018-07-04
US8685895B2 (en) 2014-04-01
US20180088128A1 (en) 2018-03-29
BRPI0922772A2 (en) 2018-11-06
ES2688621T3 (es) 2018-11-05
CA2745448C (en) 2018-09-18
CN102307897A (zh) 2012-01-04
WO2010063818A3 (en) 2010-08-12
EA026508B1 (ru) 2017-04-28
WO2010063818A2 (en) 2010-06-10
US10466252B2 (en) 2019-11-05
MX2011005874A (es) 2011-06-27
AU2009324037A1 (en) 2010-06-10
JP2015231380A (ja) 2015-12-24
EA201170762A1 (ru) 2011-12-30
BRPI0922772B1 (pt) 2021-09-08
KR20110102397A (ko) 2011-09-16
JP5840498B2 (ja) 2016-01-06
US10302655B2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
US10302655B2 (en) Methods for selecting protease resistant polypeptides
JP5030782B2 (ja) Ｔｎｆｒ１に対する単一ドメイン抗体およびその使用方法
DK2708558T3 (en) Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
KR20100018040A (ko) 프로테아제 내성 폴리펩티드를 선택하는 방법
JP2010528646A (ja) ポリペプチド、抗体可変ドメイン、およびアンタゴニスト
AU2017279662B2 (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR20080077238A (ko) 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
KR20080077237A (ko) 인터루킨 1 수용체 타입 1에 결합하는 경쟁적 도메인 항체포맷
KR20100040840A (ko) 폴리펩티드，항체 가변 도메인 및 길항제
AU2017235387B2 (en) Anti-TNFalpha-antibodies and functional fragments thereof
KR102871588B1 (ko) 항-pd-1 항체
HK1239708B (en) Anti-tnf alpha-antibodies and functional fragments thereof
HK1239708A1 (en) Anti-tnf alpha-antibodies and functional fragments thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired